Navigation Links
Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
Date:10/22/2013

e idiopathic type, the treatment of acute exacerbations of multiple sclerosis (MS) in adults, the treatment of infantile spasms (IS) in infants and children under two years of age, and the treatment of certain rheumatology related conditions. With respect to NS, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor has announced its intention to initiate a pilot commercialization effort for Acthar for the treatment of respiratory manifestations of symptomatic sarcoidosis.  The FDA-approved package insert for Acthar includes "symptomatic sarcoidosis" under the heading "Respiratory Diseases".  Questcor is also exploring the possibility of developing markets for other FDA-approved indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "ensuring," "estimates," "expects," "growth," "may," "momentum," "plans," "potential," "remain," "should," "start," "substantial," "sustainable" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
2. Morning Research: BioCryst Pharma Inc., Questcor Pharma Inc., PDL BioPharma Inc., and Amgen Inc.
3. Questcor to Commence Phase 2 Study of Acthar for ALS
4. Questcor to Report Second Quarter Financial Results on July 30, 2013
5. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
6. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
7. Questcor Adds Angus C. Russell to Board of Directors
8. Questcor Reports First Quarter Financial Results
9. Questcor to Report First Quarter Results on April 30, 2013
10. Questcor Reports Fourth Quarter and Full Year 2012 Results
11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Astellas today announced topline results from the ... safety of intravenous (IV) and oral isavuconazole, commercially ... adults with candidemia and other invasive Candida ... the trial did not meet its primary endpoint ... patients at the end of IV therapy compared ...
(Date:7/29/2015)... 29, 2015  Unilife Corporation ("Unilife" or the "Company") ... manufacturer and supplier of injectable drug delivery systems, today ... provides the Company with flexibility and control to support ... signed an equity purchase agreement for up to $45 ... Chicago -based institutional investor, which provides ...
(Date:7/29/2015)... , July 29, 2015  According to data ... Services, the 2016 average monthly Medicare Part D premium ... far lower than was originally projected, the Pharmaceutical Care ... D program continues to be a bright spot in ... choices in each region and using cutting edge, cost-saving ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Unilife Announces Multifaceted Financing Strategy 2Unilife Announces Multifaceted Financing Strategy 3Unilife Announces Multifaceted Financing Strategy 4Unilife Announces Multifaceted Financing Strategy 5
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Google Partners All-Star at the annual All-Stars Summit. Google Partners is the platform ... agencies may receive the full support and tools necessary to run successful search ...
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex ... and surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a ... with many patients from around the world. , “Like treatment of any other disease ...
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of ... easy to apply lotion or medication to a hard-to-reach area. This invention is patented. ... medication to the back, and provides thorough coverage. The product would prevent the user ...
(Date:7/30/2015)... ... 30, 2015 , ... After conducting a nationwide executive search led by healthcare ... in Far Rockaway, N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh ... healthcare leadership experience, Walsh is an expert in organizational change, physician development, implementation of ...
(Date:7/30/2015)... ... July 30, 2015 , ... According to ... not find a complete removable denture acceptable. The demand for dental implants is ... incorporate less expensive, immediate loading techniques will have the ability to offer the ...
Breaking Medicine News(10 mins):Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3
... to avoid devastating vision injuries, group says , , ... in the United States, about 40,000 people suffer ... Ophthalmology (AAO), which recommends that all athletes wear ... eye-care professional. , Lenses made from polycarbonate materials ...
... may provide protection against heart disease ... and certain cancers, ARLINGTON, ... the recognized ranks of healthful whole grains, according,to an announcement this week ... food labels to bear the whole grain health,claim. This will enable consumers ...
... International,Rescue Committee emergency team members have arrived in ... deployment to the region as the IRC,prepares for ... "Nearly all homes were destroyed in the ... no access to clean drinking water," says the,IRC,s ...
... Facility, CARSON, Calif., May 9 Leiner ... that it has submitted a,proposed agreement with the ... Court in Delaware for approval. The proposed agreement ... and distribution of certain over-the-counter (OTC) drug products ...
... for Iraq and Afghanistan Veterans Gather in Virginia to,Envision ... CHANTILLY, Va., May 9 As the war ... toll climbs above 4,000 and,casualty numbers approach the 30,000 ... on the homefront have organized to help,bereaved families and ...
... of stimulants a fixture of European nightlife, study says , , ... adults in Europe are drinking alcohol and taking drugs for ... people who are regular nightlife-goers. , The results showed ... aged 16 to 35 drink alcohol to increase their chances ...
Cached Medicine News:Health News:Protective Eyewear Key to Sports Safety 2Health News:FDA Approves Health Claim for Brown Rice 2Health News:FDA Approves Health Claim for Brown Rice 3Health News:FDA Approves Health Claim for Brown Rice 4Health News:FDA Approves Health Claim for Brown Rice 5Health News:International Rescue Committee Mobilizes More Emergency Teams for Myanmar; Warns of Massive Health Disaster Unless Aid Reaches Cyclone Survivors Fast 2Health News:Leiner Health Products Submits Proposed Agreement with Department of Justice to U.S. Bankruptcy Court for Approval 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 2Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 3Health News:Leading Veterans Service Organizations Meet Near Washington May 13-15, 2008 4Health News:Young Adults Using Alcohol, Drugs for Better Sex 2
An environmentally-safe, CN-free lytic reagent designed for use on the Abbott CELL-DYN® 1800 three-part differential hematology analyzer....
... Retics is a 5-part differential control that ... Abbott CELL-DYN 3200, 3500, 3700 and 4000 ... nucleated red blood cells that can be ... The assay contains automated and manual reticulocyte ...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
Medicine Products: